IP Library Granted Patent US 12,514,862
Granted Patent B2
US 12,514,862 · App. 17/793,640 · Granted Jan 6, 2026

Testosterone containing pharmaceutical composition

Inventors: Martin Whitaker (Cardiff, GB); John Porter (Cardiff, GB); Richard Ross (Cardiff, GB); Stewart Jones (Cardiff, GB); Elizabeth Cocks (Cardiff, GB)
Assignee: Neurocrine UK Limited
A61K31/568A61K9/48A61K47/10A61K47/44A61P5/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,514,862
App. No.
17/793,640
Granted
Jan 6, 2026
Kind
B2
Abstract

We disclose a pharmaceutical composition adapted for oral delivery comprising native testosterone; a treatment regimen comprising administration of the composition(s); and methods and uses for the treatment of hormone related conditions such as hypogonadism in human male, female and transgender subjects.

Claims (12)

1 . A pharmaceutical composition adapted for oral administration comprising at least 10-% w/w native testosterone, at least 36% w/w sesame oil, at least 28% w/w propylene glycol monolaurate, at least 9-% w/w ethanol and at least 14-% w/w benzyl alcohol.

2 . The pharmaceutical composition according to claim 1 wherein the composition comprises or consists essentially of:

(a) about 10-% w/w native testosterone;

at least 36% w/w sesame oil;

at least 28% w/w propylene glycol monolaurate;

at least 9-% w/w ethanol; and

at least 16-% w/w benzyl alcohol, or

(b) about 10% w/w native testosterone;

at least 36% w/w sesame oil;

at least 28% w/w propylene glycol monolaurate;

at least 11% w/w ethanol; and

at least 14% w/w benzyl alcohol.

Assignments (2)
CHANGE OF NAME Recorded Oct 20, 2025
From: DIURNAL LIMITED
To: NEUROCRINE UK LIMITED
Reel/Frame 072609/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2022
From: WHITAKER, MARTIN; PORTER, JOHN; ROSS, RICHARD; JONES, STEWART; COCKS, ELIZABETH
To: DIURNAL LIMITED
Reel/Frame 060726/0851 →
Priority Claims (3)
GB 2001514 · Feb 5, 2020 · national
GB 2008478 · Jun 5, 2020 · national
GB 2017853 · Nov 12, 2020 · national
Continuity (1)
Related Publication 20230066665A1 · Mar 2, 2023
References Cited (13)
US 9012436B2 · Huatan · 2015 [cited by examiner]
US 20120076855A1 · Bardani · 2012 [cited by applicant]
US 20140303129A1 · Dudley · 2014 [cited by examiner]
US 20190240237A1 · Westfield et al. · 2019 [cited by applicant]
EP 0904064B1 · 2001 [cited by examiner]
IL 208612A · 2015 [cited by examiner]
WO WO0217967 · 2002 [cited by applicant]
WO WO2005076899A2 · 2005 [cited by applicant]
WO WO2009133352A2 · 2009 [cited by applicant]
Office Action issued for Japanese Patent Application No. 2022-546091, mailed on Jan. 7, 2025. (Machine English translation). [cited by applicant]
Combined Examination and Search Report mailed on Jul. 13, 2020 in United Kingdom Application No. GB2001514.5 (7 pages). [cited by applicant]
International Search Report and Written Opinion mailed on May 19, 2021 in International Application No. PCT/EP2021/050930 (10 pages). [cited by applicant]
National Library of Medicine, clinicaltrials.gov, [online], Available from https://clinicaltrials.gov/ct2/show/NCT02966652, Nov. 2019 (9 pages). [cited by applicant]